Delivery Order SPE2DR25D1052-SPE2DR26F6CJ5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,380.39 to AmerisourceBergen Drug Corp for the supply of Orgovyx 120 mg tablets in quantities of 30 units. The contract, issued on December 11, 2025, with an ultimate completion date of January 5, 2026, operates under a firm fixed-price delivery order structure with no set-aside designation. This award represents a competitively awarded transaction reflecting AmerisourceBergen's capability to meet federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,380.39 to AmerisourceBergen Drug Corp for 30 units of Orgovyx 120 mg tablets on December 10, 2025, with completion scheduled for January 2, 2026. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,840.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 units of Orgovyx 120 mg tablets, with an ultimate completion date of December 26, 2025. This non-set-aside contract was competitively awarded on December 4, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under the company's larger pharmaceutical supply contract...
- The Defense Logistics Agency awarded a $1,385.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This is a non-set-aside competitive award with a completion date of November 18, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for the supply of Orgovyx 120 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of September 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,313.12 on September 26, 2025, for the supply of Orgovyx 120 mg tablets (30-count unit dose packages). This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 20, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,460.13 delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date of December 31, 2025. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Orgovyx 120 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $1,385.52. The award, issued on May 27, 2025, with an ultimate completion date of June 17, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $2,771.04 to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's ability to compete...
- The Defense Logistics Agency awarded a delivery order valued at $8,313.12 to AmerisourceBergen Drug Corp for the supply of Orgovyx 120 mg tablets (30-count units) on May 27, 2025, with an ultimate completion date of June 17, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance, which is also the location of AmerisourceBergen's corporate headquarters. The delivery order is a child contract...
- SPE2DR25D1052Indefinite Delivery Contract
- SPE2DR25D1052-SPE2DR26F6CJ5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Orgovyx 120 mg tablets in quantities of 30 units, with a ceiling value of $1,460.13. This competitively awarded, firm fixed-price delivery order carries an ultimate completion date of January 2, 2026, and was issued on December 10, 2025. The contract carries no set-aside designation and identifies Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. This delivery order represents a task under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceuticals and medical supplies to support military healthcare systems and other government agencies. The company has demonstrated substantial capability in fulfilling federal medical supply requirements through multiple competitive awards and maintains a diverse portfolio of pharmaceutical deliveries across numerous therapeutic domains for the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 12/9/25 |